Login / Signup

Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.

Muriel LainéSean W FanningYa-Fang ChangBradley GreenMarianne E GreeneBarry KommJustyna D KurletoLinda PhungGeoffrey L Greene
Published in: Breast cancer research : BCR (2021)
We report for the first time the anti-tumor activity of lasofoxifene in mouse models of endocrine therapy-resistant breast cancer. The results demonstrate the potential of using lasofoxifene as an effective therapy for women with advanced or metastatic ER+ breast cancers expressing the most common constitutively active ERα mutations.
Keyphrases